Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT Amendment 4)

NCT00013611 is registered in ClinicalTrials.gov with University of Minnesota as lead sponsor.

NCT NCT00013611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00013611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT Amendment 4)
Lead sponsor
University of Minnesota
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2001
Completion date
January 31, 2007
Enrollment
1,695 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection